Table 2.
Summary of current MIGS device: Clinical outcomes (% IOP reduction and change in number of medications)
| Device | Drainage | Material | % IOP reduction | Change in no. of medications | References |
|---|---|---|---|---|---|
| EX‐PRESS (200) In use |
Subconjunctival | Stainless steel |
Mean baseline IOP: 24.3 mmHg Reduction in IOP at 1 month: 11.5 mmHg (47.4% decrease) Reduction in IOP at 3 months: 11.6 mmHg (47.7% decrease) Reduction in IOP at 6 months: 12.3 mmHg (50.5% decrease) Reduction in IOP at 1 year: 11.5 mmHg (47.4% decrease) Reduction in IOP at 2 years: 10.8 mmHg (44.5% decrease) Reduction in IOP at 3 years: 12.3 mmHg (50.6% decrease) Reduction in IOP at 4 years: 13.0 mmHg (53.5% decrease) Reduction in IOP at 5 years: 12.8 mmHg (52.7% decrease) |
3.2–0.4 (87.5% decrease) | 50, 51, 52, 53, 54, 55, 56, 57 |
| iStent In use |
Schlemm's canal | Heparin‐coated titanium |
Mean baseline IOP: 22.4 mmHg Reduction in IOP at 1 month: 16.7 mmHg (25.4% decrease) Reduction in IOP at 3 months: 15.2 mmHg (32.1% decrease) Reduction in IOP at 6 months: 15.6 mmHg (30.4% decrease) Reduction in IOP at 1 year: 16.4 mmHg (26.9% decrease) Reduction in IOP at 4 years: 15.9 mmHg (29.0% decrease) |
1.5–0.2 (86.7% decrease) | 58, 59, 60 |
| iStent Inject In use |
Schlemm's canal | Heparin‐coated titanium |
Mean baseline IOP: 25.4 mmHg Reduction in IOP at 1 month: 15.7 mmHg (38.3% decrease) Reduction in IOP at 3 months: 15.4 mmHg (39.3% decrease) Reduction in IOP at 6 months: 16.8 mmHg (33.7% decrease) Reduction in IOP at 1 year: 15.7 mmHg (38.1% decrease) |
1–0 (one study) | 61, 62 |
| iStent Supra Clinical trial |
Suprachoroidal | Heparin‐coated titanium and polyethersulfone | Baseline IOP: 24.8 mmHg Reduction in IOP at 1 year: 13.2 mmHg (46.8% decrease) |
Nil data | 63 |
| Hydrus Microstent Clinical trial |
Schlemm's canal | Nitinol |
Mean baseline IOP: 23.1 mmHg Reduction in IOP at 1 month: 18.8 mmHg (18.6% decrease) Reduction in IOP at 3 months: 17.5 mmHg (24.2% decrease) Reduction in IOP at 6 months: 17.0 mmHg (26.4% decrease) Reduction in IOP at 1 year: 16.5 mmHg (28.6% decrease) |
2.1–0.7 (66.7% decrease) | 64, 65 |
| CyPass Withdrawn |
Suprachoroidal | Polyimide |
Mean baseline IOP: 24.9 mmHg Reduction in IOP at 3 months: 16.2 mmHg (35.0% decrease) Reduction in IOP at 6 months: 17.3 mmHg (30.6% decrease) Reduction in IOP at 1 year: 16.4 mmHg (34.2% decrease) Reduction in IOP at 2 years: 17.0 mmHg (31.8% decrease) |
1.8–0.8 (55.6% decrease) | 66, 67, 68 |
| Solx Approved in Canada and some European countries |
Suprachoroidal | Gold |
Mean baseline IOP: 27.0 mmHg Reduction in IOP at 1 month: 17.4 mmHg (35.5% decrease) Reduction in IOP at 3 months: 17.8 mmHg (34.2% decrease) Reduction in IOP at 6 months: 16.3 mmHg (39.6% decrease) Reduction in IOP at 1 year: 17.7 mmHg (34.2% decrease) Reduction in IOP at 2 years: 17.5 mmHg (35.1% decrease) Reduction in IOP at 3 years: 19.0 mmHg (29.5% decrease) Reduction in IOP at 5 years: 16.5 mmHg (38.8% decrease) |
2.6–1.6 (38.5% decrease) | 69, 70, 71 |
| STARflo In development |
Suprachoroidal | Porous silicone |
Mean baseline IOP: 37 mmHg Reduction in IOP at 1 year: 14.5 mmHg (60.8% decrease) |
3.3–1.5 (54.5% decrease) | 72 |
| XEN FDA approved |
Subconjunctival | Gelatin cross‐linked w/glutaraldehyde |
Mean baseline IOP: 22.2 mmHg Reduction in IOP at 1 month: 15.8 mmHg (28.9% decrease) Reduction in IOP at 3 months: 14.5 mmHg (34.8% decrease) Reduction in IOP at 6 months: 15.2 mmHg (31.6% decrease) Reduction in IOP at 1 year: 14.9 mmHg (33.0% decrease) |
3.0–0.8 (73.3% decrease) | 73, 74 |
| InnFocus Clinical trial |
Subconjunctival | SIBS |
Mean baseline IOP: 24.3 mmHg Reduction in IOP at 3 months: 9.9 mmHg (59.2% decrease) Reduction in IOP at 6 months: 10.75 mmHg (55.7% decrease) Reduction in IOP at 1 year: 10.5 mmHg (56.7% decrease) Reduction in IOP at 2 years: 11.9 mmHg (50.9% decrease) Reduction in IOP at 3 years: 10.7 mmHg (56.1% decrease) |
2.4–0.7 (70.8% decrease) | 42 |
FDA, US Food and Drug Administration; IOP, intraocular pressure; MIGS, minimally invasive glaucoma surgery; SIBS, Styrene‐block‐IsoButylene‐block‐Styrene.